|- candidate number||14125|
|- NTR Number||NTR3762|
|- ISRCTN||ISRCTN wordt niet meer aangevraagd.|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||19-dec-2012|
|- Secondary IDs||NL42339.018.12 / 2012-004634-41; CCMO / EudraCT|
|- Public Title||The nervous system and bone.|
|- Scientific Title||The role of alpha2-adrenergic receptors in bone remodeling.|
|- hypothesis||The hypothesis is that alpha2-adrenergic receptors play an important role in bone remodeling.|
|- Healt Condition(s) or Problem(s) studied||Osteoporosis|
|- Inclusion criteria||Age: 18-70 years.|
|- Exclusion criteria||1. Hypersensitivity to the active substrate or to any of the excipients;|
2. Severe bradycardia, like sick sinus syndrome and a second or third degree atrioventricular block;
3. Use of antihypertensive drugs (including diuretics);
4. Use of drugs with negative effects on heart rhythm;
5. Any medication or disease influencing bone turnover;
7. Inability to give informed consent;
8. RR < 110/70 mmHg on the day of the experiments.
|- mec approval received||yes|
|- multicenter trial||no|
|- Type||2 or more arms, randomized|
|- planned startdate ||1-feb-2013|
|- planned closingdate||30-jun-2014|
|- Target number of participants||12|
|- Interventions||After an overnight fast at bloodsamples will be drawn at 09.00 and 09.15, to determine bone turnover markers (CTX, P1NP) and catecholamine levels. After that participants will receive either a single dose of oral clonidine 0.3mg or no intervention. One, two, four and six hours later (at 10.15, 11.15, 13.15, 15.15) blood samples are drawn again to determine bone turnover markers (CTX, P1NP) and catecholamine levels.
This is a crossover design. Participants will be randomized to either clonidine followed by no intervention or no intervention followed by clonidine.
|- Primary outcome||The primary objective is to study the effect of clonidine, an alpha2-adrenergic receptor agonist, on bone resorption. We will do this by comparing the change in the bone resorption marker collagen type 1 cross-linked C-telopeptide (CTX) in healthy male and female subjects who receive a single dose of clonidine and no intervention. The changes in CTX levels on the intervention day (clonidine 0.3mg) and on the control day (no intervention) will be compared.|
|- Secondary outcome||The secondary objective is to investigate the effect of clonidine on changes in catecholamine levels and the serum concentration of the bone formation marker, procollagen type I N propeptide (P1NP) on the intervention day (clonidine 0.3mg) and on the control day (no intervention). |
|- Timepoints||Clonidine 0.3mg or no intervention (at T=9:00):|
|- Trial web site||N/A|
|- status||stopped: trial finished|
|- CONTACT FOR PUBLIC QUERIES||Dr. P.H.L.T. Bisschop|
|- CONTACT for SCIENTIFIC QUERIES||Dr. P.H.L.T. Bisschop|
|- Sponsor/Initiator ||Academic Medical Center (AMC), Amsterdam|
(Source(s) of Monetary or Material Support)
|Academic Medical Center (AMC)|
|- Brief summary||Rationale:|
Osteoporosis is a common disease that is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in increased risk of fracture. Normally, bone quality is maintained by a dynamic process, known as bone remodeling. Evidence demonstrates that the sympathetic nervous system negatively regulates bone formation and positively regulates bone resorption via beta2-adrenoceptor signaling. Regardless of the evidence that beta2-adrenoceptor signaling is a key element in the regulation of bone remodeling, both pharmacologic and genetic experiments have produced inconclusive results. Recent research suggests that beta2-adrenoceptor is not the single receptor involved in bone turnover regulation. In a mouse model of chronic elevated sympathetic tone owing to double knockout of alpha2A/2C-adrenoceptors, mice present a phenotype of high bone mass, with an increased formation and decreased bone resorption. It was also found that clonidine induced osteoclast formation and activity in vitro. These findings are in contrast with evidence that activation of the sympathetic nervous system decreases bone formation and increases bone resorption exclusively via beta2-adrenoceptor signaling. Further investigation of the specific functions of the alpha2-adrenoceptors and their interaction in bone metabolism in humans will be needed to enhance our understanding of the role of the sympathetic nervous system in the skeleton, which certainly will contribute to novel strategies for the treatment of osteoporosis.
The objective of the study is to investigate the effect of alpha2-adrenoceptors on bone turnover in humans.
Open label randomized controlled cross-over trial and observational study.
Healthy female and male human volunteers, 18-70 years old.
All participants will visit the AMC on two different occasions to receive either a single oral dose of clonidine 0.3mg or no intervention. Participants will be randomized to either clonidine followed by no intervention or no intervention followed by clondine. The first intervention will be followed by a wash out period of 1 week.
Main study parameters/endpoints:
The main study parameter is the change in serum concentrations of collagen type 1 cross-linked C-telopeptide (CTX) on the intervention day (clonidine 0.3mg) and on the control day (no intervention). A secondary study parameter is the change in serum concentrations of procollagen type I N propeptide (P1NP) and catecholamines on the intervention day (clonidine 0.3mg) and on the control day (no intervention).
|- Main changes (audit trail)|
|- RECORD||19-dec-2012 - 22-mei-2015|